Business
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
Peer-Reviewed Article Describes Clinical and Immunologic Rationale for Dual-Antigen MVA-Based Vaccine Designed to Address Limitations of First-Generation COVID-19 Vaccines in Highly Vulnerable Populations ATLANTA - March 12, 2026 (NEWMEDIAWIRE) - Ge...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Reports 2025 Year-End Financial Results and Provides Business Update","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Peer-Reviewed Article Describes Clinical and Immunologic Rationale for Dual-Antigen MVA-Based Vaccine Designed to Address Limitations of First-Generation COVID-19 Vaccines in Highly Vulnerable Populations","length":204,"tagName":"p"},{"type":"text","content":"ATLANTA - March 12, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors, today announced the publication of a peer-reviewed article describing its next-generation COVID-19 vaccine candidate, GEO-CM04S1, in Medical Research Archives, the journal of the European Society of Medicine.","length":405,"tagName":"p"},{"type":"text","content":"The article, titled "GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients," provides a comprehensive review of the vaccine's scientific rationale, preclinical studies, and clinical findings supporting its development as a vaccine designed specifically to protect immunocompromised individuals who often respond poorly to currently authorized COVID-19 vaccines.","length":396,"tagName":"p"},{"type":"text","content":"The publication highlights how GEO-CM04S1's dual-antigen design (Spike + Nucleocapsid) delivered via a Modified Vaccinia Ankara (MVA) viral vector is intended to generate antibody and T-cell responses that are both broad and durable, addressing limitations in such vulnerable populations of single-antigen vaccines that primarily target the spike protein.","length":359,"tagName":"p"},{"type":"text","content":"The publication discusses how next-generation vaccines designed to stimulate more robust and durable cellular immunity may offer improved protection for these high-risk populations.","length":181,"tagName":"p"},{"type":"text","content":"Scientific Highlights from the Publication","length":42,"tagNa...